Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma - Archive ouverte HAL Access content directly
Journal Articles American Journal of Hematology Year : 2020

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma

(1) , (2) , (3) , (4) , (5, 6, 7) , (8) , (9) , (10) , (11) , (12) , , (13) , (11) , (14) , (15) , (15) , (15) , (15) , (11) , (16)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Gilles Salles
Radhakrishnan Ramchandren
  • Function : Author

Abstract

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab alone (NCT01471210) or combined with rituximab (NCT01775631). Sixty patients received urelumab (0.3 mg/kg IV Q3W, 8 mg IV Q3W, or 8 mg IV Q6W); 46 received urelumab (0.1 mg/kg, 0.3 mg/kg, or 8 mg IV Q3W) plus rituximab 375 mg/m(2) IV QW. The maximum tolerated dose (MTD) of urelumab was determined to be 0.1 mg/kg or 8 mg Q3W after a single event of potential drug-induced liver injury occurred with urelumab 0.3 mg/kg. Treatment-related AEs were reported in 52% (urelumab grade 3/4, 15%) and 72% (urelumab + rituximab grade 3/4, 28%); three led to discontinuation (grade 3 increased AST, grade 4 acute hepatitis [urelumab]; one death from sepsis syndrome [urelumab plus rituximab]). Objective response rates/disease control rates were 6%/19% (DLBCL, n = 31), 12%/35% (FL, n = 17), and 17%/42% (other B-cell lymphomas, n = 12) with urelumab and 10%/24% (DLBCL, n = 29) and 35%/71% (FL, n = 17) with urelumab plus rituximab. Durable remissions in heavily pretreated patients were achieved; however, many were observed at doses exceeding the MTD. These data show that urelumab alone or in combination with rituximab demonstrated manageable safety in B-cell lymphoma, but the combination did not enhance clinical activity relative to rituximab alone or other current standard of care.
Fichier principal
Vignette du fichier
Timmerman et al-2020-Urelumab alone or in combination with rituximab.pdf (1.44 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

hal-02798009 , version 1 (23-06-2020)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

John Timmerman, Charles Herbaux, Vincent Ribrag, Andrew D. Zelenetz, Roch Houot, et al.. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. American Journal of Hematology, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩. ⟨hal-02798009⟩
69 View
51 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More